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tor vehicle accidents and hip fractures from falls. Evi-
dence exists showing greater risk of adverse outcomes
with higher doses of these drugs regardless of drug half-
life. Initial administration of lower doses to elderly and
debilitated patients is generally recommended for benzo-
diazepine hypnotics. We analyzed whether these recom-
mendations are generally followed when prescribing
these drugs to inpatients. METHODS: Demographic and
hospital information for all patients receiving fluraze-
pam, triazolam, or temazepam between January 1998
and June 2000 was extracted from Solucient’s Projected
Inpatient International Classification of Clinical Services
(pICCS) database. This database contains demographic,
hospital, clinical, and detailed service level information
for inpatients from over 150 short-term, non-federal, US
hospitals. The percent of elderly patients (over age 65) re-
ceiving the recommended dose was determined. The rela-
tionship of patient age, hospital teaching status, bed size,
and geographic region on the likelihood of following dos-
ing recommendations was analyzed. RESULTS: We ex-
tracted information for 14,929 inpatients receiving flu-
razepam, 8,147 inpatients receiving triazolam, and 125,625
patients receiving temazepam. Among elderly patients re-
ceiving one of these drugs, 72.1% of patients receiving
flurazepam, 49.8% of patients receiving temazepam, and
7.1% of patients receiving triazolam received the recom-
mended dose. For all three drugs, patient age was directly
correlated with the likelihood of receiving the recom-
mended dose. There was no consistent relationship be-
tween teaching status, hospital bed size, or geographic re-
gion and the likelihood of receiving the recommended
dose, although teaching hospitals were much more likely
than non-teaching hospitals to provide the recommended
dose for temazepam and triazolam (OR 5.3 CI 4.9–5.8
for temazepam; OR 2.7 CI 2.2–3.2 for triazolam). CON-
CLUSIONS: Many elderly inpatients are prescribed higher
than recommended doses of hypnotic benzodiazepines,
suggesting need for systemic interventions to avert ad-
verse outcomes.
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OBJECTIVES: The detrimental effects of hospitalisation
and developments in psychopharmaceutical, psychother-
apeutic and social treatments led to deinstitutionaliza-
tion. Proxies of patients, relatives or friends, have had to
learn to cope with caregiving tasks. Facilitating the cop-
ing of the caregivers should ensure a better quality of
caregiving, notably in terms of therapeutical observance.
An exhaustive literature review found 9 instruments for
caregivers of schizophrenic patients. Five of them are self
administered, but none of those covering mental, psycho-
logical and social fields have been widely validated and
accepted within the scientific community, none are avail-
able in French. We report the first step of development of
a specific, multidimensional, self-administered instru-
ment measuring the quality of life of non-institutional
caregivers of schizophrenic patients. METHODS: Face-
to-face interviews were conducted with non-institutional
caregivers of schizophrenic patients. Their content was
analysed to generate a large number of candidate items
covering all-important aspects of caregivers’ quality of
life. Eighteen interviews were performed: 11 mothers and
7 fathers aged from 48 years to 71. RESULTS: Content
analysis identified topics covering mental (worrying,
emotional over-involvement, and suffering, guilt, fair of
stigma, of future, loneliness, disillusion, anxiety, feeling
of usefulness, self esteem . . . ) physical (fatigue, disrup-
tion of sleep . . . ) and social (relationships with the pa-
tient, friends, relatives, health workers, occupation, lei-
sure . . . ) fields. Negative as well as positive impact was
identified. CONCLUSIONS: These results were compared
to the domains described in the literature. This step led to
the generation of about 100 questions and the validity of
this questionnaire will be studied on 400 caregivers.
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OBJECTIVES: To assess differences in the health care re-
source use of patients who received selective serotonin
reuptake inhibitor (SSRI) antidepressants. METHODS:
Retrospective analysis of administrative medical claims
from 1/97–12/99 was conducted using Protocare Sci-
ences’ Managed Care Database. Patients were catego-
rized as early discontinued or continued (6 months vs.

6 months therapy), then as non-switched or switched
(one agent vs. one agent). Total health care costs were
compared across these categories. RESULTS: Under half
(48%) of the 11,119 SSRI users studied continued antide-
pressant therapy for at least 6 months. Two-thirds of all
patients received monotherapy; 19% switched agents
(44% of switches were in the first three months of ther-
apy); 15% used multiple agents. Eight percent of patients
who discontinued early had switched agents within the
specified 6 month period; 90% of these switches occurred
in the first three months. For patients who continued ther-
apy for 
6 months, the average total health care charges
per patient per month (PPPM) during the first three therapy
months were $906 (switch by third month), $568 (switch
by sixth month), $496 (switch by twelfth month) and $375
(switch after twelfth month). PPPM charges in the first six
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therapy months ranged from $452–$921 for discontinued
patients and from $423–$483 for non-switched, contin-
ued patients. CONCLUSIONS: Patients who discontinued
SSRI therapy early tended to have higher costs than pa-
tients who continued therapy. It is unclear whether these
increased costs stem from treatment of medication side
effects or increased utilization related to lack of efficacy
of the initial antidepressant. Alternatively, early switchers
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OBJECTIVES: In France a large part of acute hospitalisa-
tion beds are occupied by long-term hospitalisation of
schizophrenic patients. A model was developed to com-
pare Intensive Case Management (ICM) to Standard Case
Management (SCM) for long-term hospitalised chronic
schizophrenic patients. METHODS: A model was used
to evaluate the number of patients that are either success-
fully dechronized, experiencing failure, or are readmitted
to hospital within a year for a cohort of 100 chronic
schizophrenic patients. With these figures, it was possible
to estimate the needs in terms of number of beds and em-
ployees in the catchment area of Clermont-Ferrand in
France, for the 1st, 2nd and 3rd year after the ICM strat-
egy have been implemented. RESULTS: At the beginning
of the first year, 100 hospitalisation beds, 30 nurses, 10
psychologists and 5 psychiatrists were needed. After 1
year these numbers were respectively reduced to 50, 15,
10 and 2.5 due to the success of the ICM strategy. This
positive trend is also recorded for the second year of im-
plementation. At the end of the 3rd year a steady point
level is nevertheless reached with the model, due to the
fact that there will always be patients that can not be
dechronized; the numbers at this point will be 11 beds, 3
nurses, 1 psychologist and a half-time psychiatrist. CON-
CLUSIONS: Due to the important caseload of ICM, it re-
mains more costly than SCM at implementation, but will
reduce cost from year 1, and be less costly than SCM
from year 3. This model can therefore evaluate the eco-
nomic impact of creating a dechronization unit in a
catchment area and make budgetary prevision for large-
scale implementation of ICM in France.
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BACKGROUND: It has been reported that approxi-
mately 1% of young women have anorexia nervosa and
4% bulimia. Managing eating disorders requires a multi-
disciplinary approach including acute hospitalization,
when necessary. This study was undertaken to assess the
cost of acute hospital care for these disorders. METH-
ODS: Inpatient cost estimates, adjusted for medical infla-
tion and cost-to-charge ratios, were developed using data
from all-payer 1998 discharge databases from five states,
supplemented with national fee schedules. ICD9 codes
were used to identify those with a principal diagnosis of
anorexia (307.1) or bulimia (307.51). Cases where both
diagnoses were coded are excluded from results reported
here. Log transformation was used to address highly
skewed distributions. Length-of-stay (LOS), disposition
and psychiatric unit care (PSYU) were also examined.
Hospital costs (i.e., accommodation, ancillary, physician)
are reported in 2000 US$. RESULTS: The state databases
yielded 641 cases of anorexia and 326 of bulimia. The
overwhelming majority (96%) were females. For anor-
exia: the mean age was 25 years (45% 20 years); mean
LOS was 13; 24% received care in a PSYU; 87% were
discharged home; 7% went to a rehab or mental health
facility (MHF) and 3% left against medical advice
(AMA). For bulimia, the mean age was 27 years (25%
20 years); mean LOS was 9; 39% received care in a
PSYU; 90% were discharged home; 4% to rehab or
MHF; 3% left AMA. The mean total cost per hospital
stay was $12,390 for anorexia and $9,120 for bulimia.
On average, the number of annual admissions was 1.6
and 1.2 for anorexia and bulimia, respectively. Managed
care was the largest primary payer. CONCLUSIONS: Al-
though hospitalization is not the primary site of medical
care for managing serious eating disorders, it’s sometimes
required. We believe that this information provides an es-
sential piece in understanding the economic consequences
of these conditions.
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OBJECTIVE: To estimate and compare the efficacy,
treatment-emergent adverse events, costs and outcomes
of olanzapine and ziprasidone for treatment of schizo-
phrenia. METHODS: A decision-analytic model was
used to determine outcomes for patients treated over a
1-year period. Model parameters were based on clinical
trial data and published medical literature. Data from
different trials were compared only when patient popula-
tions were similar. Comparative studies were available
for weight gain and cardiovascular events. For essential
parameters with no relevant study results, assumptions
were made that the medications would be similar. RE-
